Center for Cancer Research, National Cancer Institute, National Institutes of Health

1 ARTICLES PUBLISHED IN JoVE

Developmental Biology

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Yang Jo Chung¹, Ghanwa Khawaja¹, Karen M. Wolcott², Peter D. Aplan¹

¹Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, ²LGI Flow Cytometry Core Facility, Center for Cancer Research, National Cancer Institute, National Institutes of Health

We describe the use of hematopoietic stem cell transplantation (HSCT) to assess the malignant potential of genetically engineered hematopoietic cells. HSCT is useful for evaluating various malignant hematopoietic cells in vivo as well as generating a large cohort of mice with myelodysplastic syndromes (MDS) or leukemia to evaluate novel therapies.